268 related articles for article (PubMed ID: 27645621)
1. Patterns of recurrence and survival in neuroendocrine cervical cancer.
Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population.
Zhang X; Lv Z; Lou H
BMC Cancer; 2019 Jan; 19(1):22. PubMed ID: 30616631
[TBL] [Abstract][Full Text] [Related]
4. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.
Boruta DM; Schorge JO; Duska LA; Crum CP; Castrillon DH; Sheets EE
Gynecol Oncol; 2001 Apr; 81(1):82-7. PubMed ID: 11277655
[TBL] [Abstract][Full Text] [Related]
5. Exploring a Better Adjuvant Treatment for Surgically Treated High-Grade Neuroendocrine Carcinoma of the Cervix.
Wang R; Xiao Y; Ma L; Wu Z; Xia H
Gynecol Obstet Invest; 2022; 87(6):398-405. PubMed ID: 36273460
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors and Impact of Minimally Invasive Surgery in Early-stage Neuroendocrine Carcinoma of the Cervix.
Kim JH; Shim SH; Nam SH; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
J Minim Invasive Gynecol; 2020; 27(7):1558-1565. PubMed ID: 32084588
[TBL] [Abstract][Full Text] [Related]
7. Natural history and outcome of neuroendocrine carcinoma of the cervix.
Margolis B; Tergas AI; Chen L; Hou JY; Burke WM; Hu JC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2016 May; 141(2):247-254. PubMed ID: 26873865
[TBL] [Abstract][Full Text] [Related]
8. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.
Viswanathan AN; Deavers MT; Jhingran A; Ramirez PT; Levenback C; Eifel PJ
Gynecol Oncol; 2004 Apr; 93(1):27-33. PubMed ID: 15047210
[TBL] [Abstract][Full Text] [Related]
9. Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer.
Pan B; Wan T; Jiang Y; Zheng X; Liu P; Xiang H; Zheng M
BMC Cancer; 2022 Jun; 22(1):655. PubMed ID: 35698184
[TBL] [Abstract][Full Text] [Related]
10. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases.
Lan-Fang L; Hai-Yan S; Zuo-Ming Y; Jian-Qing Z; Ya-Qing C
Eur J Gynaecol Oncol; 2012; 33(1):68-73. PubMed ID: 22439409
[TBL] [Abstract][Full Text] [Related]
11. Distant organ metastasis patterns and prognosis of neuroendocrine cervical carcinoma: a population-based retrospective study.
Li Q; Yu J; Yi H; Lan Q
Front Endocrinol (Lausanne); 2022; 13():924414. PubMed ID: 36051393
[TBL] [Abstract][Full Text] [Related]
12. Surgical treatment for neuroendocrine carcinoma of the uterine cervix.
Kasamatsu T; Sasajima Y; Onda T; Sawada M; Kato T; Tanikawa M
Int J Gynaecol Obstet; 2007 Dec; 99(3):225-8. PubMed ID: 17897648
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma.
Li H; Li X; Yang M; Su H; Zhang J; Hu C; Sun Y; Hu D; Chen L
J Clin Transl Res; 2023 Aug; 9(4):272-281. PubMed ID: 37593242
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
Salvo G; Flores Legarreta A; Ramalingam P; Jhingran A; Bhosale P; Saab R; Gonzales NR; Chisholm GB; Frumovitz M
Int J Gynecol Cancer; 2023 Sep; 33(9):1359-1369. PubMed ID: 37567596
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
Goto S; Terao Y; Kamigaki T; Takimoto R; Naitoh K; Makita K; Yasumoto K; Okada S; Takizawa K; Yokomichi N; Suzuki N; Takeda S
Anticancer Res; 2020 Aug; 40(8):4741-4748. PubMed ID: 32727800
[TBL] [Abstract][Full Text] [Related]
17. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study.
Lee SW; Nam JH; Kim DY; Kim JH; Kim KR; Kim YM; Kim YT
Int J Gynecol Cancer; 2010 Apr; 20(3):411-6. PubMed ID: 20375806
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.
Gadducci A; Landoni F; Cosio S; Zizioli V; Zola P; Ferrero AM; Lapresa MT; Maggino T; Sartori E
Anticancer Res; 2018 Jun; 38(6):3627-3634. PubMed ID: 29848719
[TBL] [Abstract][Full Text] [Related]
20. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.
Robin TP; Amini A; Schefter TE; Behbakht K; Fisher CM
Brachytherapy; 2016; 15(6):845-850. PubMed ID: 27720204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
